|
Session 43-Oral Abstracts
Hepatitis C: Transmission, Outcomes, and Treatment
Friday, 9:30 am-12 noon; Room 3022 |
| 9:30 am 162 |
The Interleukin 28B Gene and HCV Recovery
Andri Rauch
Univ Hosp Bern, Switzerland |
| 10:00 am 163 |
Association of IL28B Haplotypes with Chronic HCV Infection in HIV/HCV Co-infected Individuals
Julia di Iulio*1, P-Y Bochud1, M Rotger1, H Furrer2, F Negro3, A Telenti1, A Rauch2, and Swiss HIV and HCV Cohort Studies
1Univ Hosp Lausanne and Univ of Lausanne, Switzerland; 2Univ Hosp Bern and Univ of Bern, Switzerland; and 3Univ Hosp Geneva, Switzerland |
| 10:15 am 164 |
Genetic Variation in IL28B and Treatment-induced Clearance of HCV in HCV/HIV Co-infected Patients
Jacob Nattermann*1, M Vogel1, A Baumgarten2, U Naumann3, H-J Stellbrink4, M Danta5, C Tural6, R Bruno7, U Spengler1, and J Rockstroh1
1Univ of Bonn, Germany; 2Private Practice, Berlin, Germany; 3Praxiszentrum Kaiserdamm, Berlin, Germany; 4ICH, Hamburg, Germany; 5St Vincent’s Clin Sch, Australia; 6Hosp Univ Germans Trias i Pujol, Autonomos Univ of Barcelona, Spain; and 7Univ of Pavia IRCCS, San Matteo Hosp, Italy |
| 10:30 am 165LB |
Strong Association of a Single Nucleotide Polymorphism Located Near the Interleukin-28b Gene with Response to Hepatitis C Therapy in HIV/HCV Co-infected Patients
Norma Rallon*1, S Naggie2, J Benito1, J Medrano1, C Restrepo1, D Goldstein3, K Shianna3, J McHutchison2, and V Soriano1
1Hosp Carlos III, Madrid, Spain; 2Duke Clin Res Inst, Durham, NC, US; and 3Inst for Genome Sci and Policy, Durham, NC, US |
| 10:45 am 166 |
Baseline Liver Disease Is Independently Associated with Risk of Death among 631 HIV/HCV Co-infected Adult with Histologic Staging
Mark Sulkowski*, S Mehta, C Sutcliffe, M Torbenson, Y Higgins, B Limketkai, R Moore, and D Thomas
Johns Hopkins Univ, Baltimore, MD, US |
| 11:00 am 167 |
Sustained Virological Response to Interferon plus Ribavirin Reduces HIV Progression and Non-liver-related Mortality in Patients Co-infected with HIV and HCV
Juan Berenguer*1, M Crespo2, M Galindo3, M Téllez4, C Barros5, J Guardiola6, R Rubio7, E Barquilla8, J Bellón1, J González-García9, and Gesida 3603 Study Group
1Hosp Univ Gregorio Marañon, Madrid, Spain; 2Hosp Univ Bellvitge, Spain; 3Hosp Clin Valencia, Spain; 4Hosp Clin San Carlos, Spain; 5Hosp de Mostoles, Spain; 6Hosp Santa Creu y Sant Pau, Spain; 7Hosp 12 de Octubre, Madrid, Spain; 8Fndn SEIMC-GESIDA, Spain; and 9Hosp Univ La Paz, Madrid, Spain |
| 11:15 am 168 |
Survival of HCV in Syringes: Implication for HCV Transmission among Injection Drug Users
Elijah Paintsil*, H He, C Peters, B Lindenbach, and R Heimer
Yale Sch of Med, New Haven, CT, US |
| 11:30 am 169 |
HCV Transmission and Diversification in Infected Subjects Analyzed by Deep Sequencing
Gary Wang*1,2, S Sherrill-Mix2, K-M Chang2, C Quince3, and F Bushman2
1Univ of Florida, Gainesville, US; 2Univ of Pennsylvania, Philadelphia, US; and 3Univ of Glasgow, UK |
| 11:45 am 170LB |
Ultra-deep Sequencing Analysis Demonstrates Pre-existence of HBV Resistance Substitutions at Baseline in Patients Who Subsequently Develop Clinical Resistance
Christophe Rodriguez*, S Chevaliez, C Pallier, and J-M Pawlotsky
INSERM U955, Hosp Henri Mondor, Univ Paris 12, Créteil, France |
|
